AstraZeneca's Lynparza nabs accelerated review in U.S. for prostate cancer

• The FDA grants Priority Review status to AstraZeneca's (NASDAQ:AZN) Lynparza (olaparib) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations who have progressed following prior treatment with a new hormonal agent.
• The agency's action date is next quarter.
• Shares down 2% premarket on light volume.
• Related ticker: Merck (NYSE:MRK)

Comments

[SuperPac]

A great stock...had a fantastic 2019 for the right reasons. Keep an eye on this one for opportune position-taking.

[5ofDiamonds]

Someone mentioned that while analysts are claiming to invest outside US to find value in Europe/Emerging markets, the top stocks there are also overvalued @SuperPac

$AZN also trading near 52WH.

[SuperPac]

It is. But worth nibbling if you spot a 10% correction. Read the last few news items about it in SA. Many good things lined up. GSK too is doing a few good things in its portfolio and how it allocates capital.

[5ofDiamonds]

Thanks @SuperPac

I might nibble $AZN to keep it on my radar. 10% corrections are hard to find.